Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

RMD open

Showing results (451-460 of 2,090) with videos related to

Pageof 209
Sort By:
RMD Open|April 12, 2024
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritisYun-Kyoung Song, Jaehee Lee, Junwoo Jo, et al.
RMD Open|April 5, 2024
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT registerTatjana Rudi, Vera Zietemann, Yvette Meissner, et al.
RMD Open|February 23, 2024
New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritisAlessandro Tomelleri, Christian Dejaco
RMD Open|February 27, 2024
Window of opportunity in psoriatic arthritis: the earlier the better?Selinde V J Snoeck Henkemans, Pascal H P de Jong, Jolanda J Luime, et al.
RMD Open|February 21, 2024
Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, NorwayIngebjørg Tronstad, Mari Hoff, Julie Horn, et al.
RMD Open|February 22, 2024
Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDsShotaro Kojima, Taro Iwamoto, Yoshihisa Kobayashi, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
RMD Open|February 5, 2024
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind studyAnna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, et al.
RMD Open|February 2, 2024
Health inequities and societal costs for patients with fibromyalgia and their spouses: a Danish cohort studyKirstine Amris, Rikke Ibsen, Pernille Hurup Duhn, et al.
RMD Open|January 31, 2024
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritisBenoît Thomas P Gilbert, Raul Yhossef Tito Tadeo, Celine Lamacchia, et al.
Pageof 209

Showing results (451-460 of 2,090) with videos related to

Sort By:
Pageof 209
RMD Open|April 12, 2024
Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritisYun-Kyoung Song, Jaehee Lee, Junwoo Jo, et al.
RMD Open|April 5, 2024
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT registerTatjana Rudi, Vera Zietemann, Yvette Meissner, et al.
RMD Open|February 23, 2024
New blood biomarkers and imaging for disease stratification and monitoring of giant cell arteritisAlessandro Tomelleri, Christian Dejaco
RMD Open|February 27, 2024
Window of opportunity in psoriatic arthritis: the earlier the better?Selinde V J Snoeck Henkemans, Pascal H P de Jong, Jolanda J Luime, et al.
RMD Open|February 21, 2024
Rheumatoid arthritis, disease-modifying antirheumatic drugs and risk of major osteoporotic fracture: prospective data from the HUNT Study, NorwayIngebjørg Tronstad, Mari Hoff, Julie Horn, et al.
RMD Open|February 22, 2024
Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDsShotaro Kojima, Taro Iwamoto, Yoshihisa Kobayashi, et al.
RMD Open|February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITALLaura C Coates, Robert Landewé, Iain B McInnes, et al.
RMD Open|February 5, 2024
Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind studyAnna Zubrzycka-Sienkiewicz, Kamilla Klama, Martin Ullmann, et al.
RMD Open|February 2, 2024
Health inequities and societal costs for patients with fibromyalgia and their spouses: a Danish cohort studyKirstine Amris, Rikke Ibsen, Pernille Hurup Duhn, et al.
RMD Open|January 31, 2024
Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritisBenoît Thomas P Gilbert, Raul Yhossef Tito Tadeo, Celine Lamacchia, et al.
Pageof 209